IP Library Granted Patent US 11,938,113
Granted Patent B2
US 11,938,113 · App. 16/766,175 · Granted Mar 26, 2024

Epigallocathechin gallate solution

Inventors: Bernard Do (Issy-les-Moulineaux, FR); Muriel Paul (Montevrain, FR); Alain Astier (Paris, FR)
Assignees: ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS; UNIVERSITE PARIS-SACLAY
A61K31/352A61K8/362A61K8/498A61K8/60A61K47/12A61K47/26A61Q19/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,938,113
App. No.
16/766,175
Granted
Mar 26, 2024
Kind
B2
Abstract

A stable pharmaceutical or dermo-cosmetic aqueous solution of epigallocatechin gallate is provided. The present solution has improved EGCG solubility, stability and bioavailability.

Claims (29)

1. A stable pharmaceutical or dermo-cosmetic aqueous solution comprising:

13-107 mg/ml of epigallocatechin gallate,

at least one disaccharide,

0.1-1.0 mmol/l of at least one chelating agent,

a pharmaceutically acceptable or dermo-cosmetically acceptable pH-modifying agent, and

wherein said solution is at a pH in a range of 3.0 to 4.0 and the molar ratio of epigallocatechin gallate/disaccharide is from 0.1 to 0.8.

2. The pharmaceutical or dermo-cosmetic aqueous solution according to claim 1 , wherein the disaccharide is chosen from sucrose and trehalose.

3. The pharmaceutical or dermo-cosmetic aqueous solution according to claim 1 , further comprising at least one antioxidant agent suitable for the aqueous systems and compatible with acidic pH, chosen from ascorbic acid, erythorbic acid, monothioglycerol, sodium metabisulfite and sodium bisulfate, and reducing sugar.

4. The pharmaceutical or dermo-cosmetic aqueous solution according to claim 1 , wherein said solution is exempt of organic solvent.

5. The pharmaceutical or dermo-cosmetic aqueous solution according to claim 1 , wherein said solution further comprises an organic solvent chosen from ethanol, propylene glycol, glycerol, and PEG 400.

6. The pharmaceutical or dermo-cosmetic aqueous solution according to claim 1 , wherein the chelating agent is chosen from citric acid, calcium disodium edetate, disodium edetate, fumaric acid, malic acid, maltol and pentetic acid.

7. The pharmaceutical or dermo-cosmetic aqueous solution according to claim 1 , wherein the pharmaceutically acceptable pH-modifying agent is chosen from acetic acid, adipic acid, ammonium carbonate, ammonium hydroxide, ammonium phosphate, citric acid, diethanolamine, fumaric acid, hydrochloric acid, malic acid, nitric acid, proprionic acid, potassium acetate, potassium bicarbonate, potassium chloride, potassium citrate, potassium metaphosphate, potassium phosphate, sodium acetate, sodium bicarbonate, sodium carbonate, sodium citrate, sodium glycolate, sodium hydroxide, sodium lactate, sodium phosphate, sodium proprionate, succinic acid, sulfuric acid, tartaric acid, and triethanolamine.

8. The pharmaceutical or dermo-cosmetic aqueous solution according to claim 1 , comprising:

13-107 mg/ml, of epigallocatechin gallate

0.05-3.0 mg/ml, of citric acid,

25-140 mg/ml, of sucrose, and

optionally, 25-250 mg/ml, of glucose and/or fructose.

9. The pharmaceutical or dermo-cosmetic aqueous solution according to claim 8 , comprising:

27 mg/ml of epigallocatechin gallate

0.1 mg/ml of citric acid

100 mg/ml of sucrose, and

100 mg/ml of glucose.

10. The pharmaceutical aqueous solution of claim 1 , a unit dose of epigallocatechin gallate comprising said pharmaceutical aqueous solution or a solid composition of said pharmaceutical aqueous solution or a solid composition of said unit dose for its use as a medicament in the treatment of cancers, cardiovascular disorder, diabetes, neurodegenerative diseases, or dermatological diseases.

11. A unit dose of epigallocatechin gallate comprising the pharmaceutical or dermo-cosmetic aqueous solution according to claim 1 .

12. The unit dose according to claim 11 , wherein said unit dose has a volume in the range of 5-30 ml.

13. The unit dose according to claim 11 , wherein epigallocatechin gallate has a weight in the range of 200-1600 mg.

14. A solid composition resulting from any water removal process of the pharmaceutical or dermo-cosmetic aqueous solution of claim 1 or of a unit dose of epigallocatechin gallate comprising said pharmaceutical or dermo-cosmetic aqueous solution.

15. A dermo-pharmaceutical product comprising the pharmaceutical aqueous solution of claim 1 , a unit dose of epigallocatechin gallate comprising said pharmaceutical aqueous solution or a solid composition of said pharmaceutical aqueous solution or a solid composition of said unit dose.

16. A dermo-cosmetic product comprising the dermo-cosmetic aqueous solution of claim 1 or a solid composition of said dermo-cosmetic aqueous solution.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2020
From: DO, BERNARD; PAUL, MURIEL; ASTIER, ALAIN
To: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS; UNIVERSITE PARIS-SACLAY (FORMERLY KNOWN AS UNIVERSITE PARIS-SUD)
Reel/Frame 052731/0637 →
CHANGE OF NAME Recorded May 22, 2020
From: UNIVERSITE PARIS-SUD
To: UNIVERSITE PARIS-SACLAY
Reel/Frame 052742/0660 →
Priority Claims (1)
EP 17306623 · Nov 23, 2017 · regional
Continuity (1)
Related Publication 20200375939A1 · Dec 3, 2020